BFC Planning’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$139K Sell
9,500
-5,000
-34% -$47.4K 0.01% 1091
2026
Q2
$114K Buy
+14,500
New +$70.9K ﹤0.01% 1183

Other funds holding ABCL

BFC Planning's ABCL Position: Q3 2026 in Review

BFC Planning reduced its AbCellera Biologics (ABCL) stake by 34% in Q3 2026, selling an estimated $47.4K and leaving 9,500 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #1091.

BFC Planning first reported a position in ABCL in Q2 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • BFC Planning held 9,500 shares of AbCellera Biologics worth $139K as of Q3 2026.
  • BFC Planning sold 5,000 AbCellera Biologics shares in Q3 2026, an estimated $47.4K.
  • AbCellera Biologics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #1091 holding.
  • BFC Planning first reported a position in AbCellera Biologics in Q2 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.